Home Tags Takeda

Tag: Takeda

Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin lymphoma: Study...

The final data of the brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda Oncology) monotherapy pivotal phase II clinical trial in relapsed or refractory (R/R) classical Hodgkin...

European Commission Approves Brentuximab Vedotin for Consolidation Treatment in Post-Transplant Hodgkin...

The European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology) and approved the drug for the treatment of...

Commercial and Regulatory Progress under Brentuximab Vedotin Collaboration Between Seattle Genetics...

Nearly 7 years ago, in 2009, Seattle Genetics, a clinical stage biopharmaceutical company, and Takeda Pharmaceuticals, Japan's largest pharmaceutical company with a 230+ year...

Mersana and Takeda Expand Partnership to Advance Development of Fleximer® based...

Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new, expanded, strategic partnership.  Under the terms of the agreement,  Takeda...

Millennium/Takeda Exercises Commercial License Right for Fleximer Technology

Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited has exercised an option to license commercial rights for its first novel Fleximer® antibody-drug conjugate or ADC developed as part of their collaboration with Mersana Therapeutics, announced earlier this year.

Brentuximab Vedotin Shows 42% Objective Response Rate in Patients with Relapsed...

New, updated, data from a phase II clinical trial of brentuximab vedotin (Adcetris®; Seattle Genetics) in patients with diffuse large B-cell lymphoma or DLBCL and other B-cell non-Hodgkin lymphomas, demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results were presented at the 55th annual meeting of ASH®, the American Society of Hematology, held in New Orleans, Louisiana, USA, from December 7 - 10, 2013.

Updated Data for Brentuximab Vedotin Shows Durable Complete Remission and Manageable...

Updated data from a pivotal trial of single-agent brentuximab vedotin (adcetris™,Seattle Genetics) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)...